A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms …

F Passamonti, F Cervantes… - Blood, The Journal …, 2010 - ashpublications.org
F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, P Guglielmelli
Blood, The Journal of the American Society of Hematology, 2010ashpublications.org
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell
count greater than 25× 109/L, peripheral blood blasts 1% or higher, and constitutional
symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at
diagnosis. To investigate whether the acquisition of these factors during follow-up predicts
survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant
impact on survival when analyzed as time-dependent covariates in a multivariate Cox …
Abstract
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 × 109/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.
ashpublications.org